2023 Press Releases 2023 2022 2021 2020 2019 Portfolio Companies New Leaf Portfolio Companies Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune PipelineAugust 17, 2023 Lilly Completes Acquisition of DICE TherapeuticsAugust 9, 2023 PASSAGE BIO ANNOUNCES PROMISING INTERIM CLINICAL DATA FROM FIRST EIGHT PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDYAugust 7, 2023 Thoma Bravo Announces Strategic Growth Investment in Bluesight to Support the Company’s Acquisition of MedacistJuly 17, 2023 HARPOON THERAPEUTICS ANNOUNCES COMPLETION OF PLANNED PATIENT ENROLLMENT IN PHASE 1 STUDY OF HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMAJune 27, 2023 Edgewise Therapeutics Announces Positive 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD)June 26, 2023 Silver Cross Hospital Expands Use of Kyruus’ Award-Winning Online Scheduling Solution Across Specialties and ServicesJune 20, 2023 Lilly to Acquire DICE Therapeutics to Advance Innovation in ImmunologyJune 20, 2023 Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H MutationsJune 8, 2023 COGENT BIOSCIENCES ANNOUNCES PRICING OF UPSIZED PUBLIC OFFERING OF SHARES OF COMMON STOCKJune 6, 2023 COGENT BIOSCIENCES ANNOUNCES POSITIVE LEAD-IN DATA FROM ONGOING PHASE 3 PEAK TRIAL EVALUATING BEZUCLASTINIB IN COMBINATION WITH SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)June 3, 2023 Cleerly Partners with ProScan Imaging to Transform the Standard of Care for Heart Disease PreventionJune 1, 2023 Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand DiseaseMay 23, 2023 CostCheck From Bluesight Wins 2023 MedTech Breakthrough AwardMay 10, 2023 Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical TrialMay 2, 2023 COGENT BIOSCIENCES PRESENTS PRECLINICAL DATA AT AACR ANNUAL MEETING HIGHLIGHTING PRECISION THERAPY PIPELINE AND ANNOUNCES INITIATION OF PART 2 OF THE REGISTRATION-ENABLING APEX TRIAL WITH BEZUCLASTINIB IN ADVANCED SYSTEMIC MASTOCYTOSISApril 17, 2023 Thrombocytopenia (FNAIT), Published in the Journal of Thrombosis and HaemostasisApril 6, 2023 Intermountain Health Expands Relationship with Kyruus to Create Foundation for Rebranded Digital ExperienceApril 5, 2023 Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)April 3, 2023 TigerConnectAppoints Two SaaS Leaders to Drive Product Enhancements and Revenue GrowthMarch 24, 2023 BrightInsight Named to Fierce Medtech’s 2022 Fierce 15 ListMarch 20, 2023 Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18March 14, 2023 Rallybio Announces Proof-of-Concept Achieved for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune ThrombocytopeniaMarch 6, 2023 Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series SessionJanuary 24, 2023 BrightInsight Welcomes ixlayer to the BrightInsight Ecosystem to Streamline Diagnosis and Improve Therapy MatchingFebruary 22, 2023 Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series SessionJanuary 24, 2023 Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesJanuary 24, 2023 Kyruus Reports Landmark Year, Cementing Position as a Foundational Digital Health PlatformJanuary 9, 2023
